Korsana Biosciences, Inc. Common Stock
KRSA
17 hedge funds and large institutions have $1.06M invested in Korsana Biosciences, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
13% more capital invested
Capital invested by funds: $932K → $1.06M (+$124K)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
2.48% less ownership
Funds ownership: 13.78% → 11.3% (-2.5%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$729 |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$481 |
| 3 |
PW
Pandora Wealth
Oakbrook Terrace,
Illinois
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tyndall Capital Partners
New York
|
-$4.09K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.4K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$149 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$87 |
| 5 |
EWP
Elevation Wealth Partners
Santa Rosa,
California
|
-$50 |
KRSA Hedge Fund Activity: Q2 2025 in Review
17 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2025, worth a combined $1.06M — up 13% from $932K a quarter earlier.
Fund positioning in KRSA was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $729. The largest seller was Tyndall Capital Partners, cutting an estimated $4.09K.
- 17 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $1.06M of Korsana Biosciences, Inc. Common Stock stock for Q2 2025, up 13% quarter-over-quarter.
- 1 fund opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2025 was Tower Research Capital (TRC), an estimated $729 added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q2 2025 was Tyndall Capital Partners, an estimated $4.09K sold.
Based on aggregated 13F filings for Q2 2025.